Medically Associated Science and Technology Program
The Medically Associated Science and Technology (MAST) program at Cedars-Sinai is dedicated to the development of novel drugs and devices to diagnose and treat patients. MAST represents the mainsail of a vessel taking us on a voyage of discovery in medicine and science. This innovative program is working to develop new diagnostics and therapeutics to treat patients with illnesses related to imbalances or alterations in the microbiome. Over the last 20 years, the MAST team has made many discoveries that benefit millions of patients, and we hope to help millions more with our growing fleet of novel diagnostics and therapeutics.
At MAST, patients are at the center of our work, which gives us a unique perspective as we innovate. Having direct interactions with patients drives our curiosity toward clinically meaningful questions and allows us to move quickly toward identifiable solutions. The MAST team brings expertise in working with the microbiome in both basic and clinical aspects, along with a track record of navigating the U.S. Food and Drug Administration (FDA) approval process and post-FDA approval work.
The microbiome is the cluster of bacteria and flora that live within us, and can influence our health and wellbeing. The MAST program is determined to study the gut microbiome using lab research and clinical studies. Learn more about the research and advances in the MAST program.
The Medically Associated Science and Technology (MAST) program at Cedars-Sinai is centered on accelerating medical technologies to treat human disease through a hospital-based approach to drug and device development. The MAST patient-focused strategy brings patients and medical innovators together to accelerate the development of novel therapies that are highly relevant to human conditions. At this time, based on the strengths of our expert team, MAST focuses on technologies to diagnose and treat microbiome-based disorders as well as metabolic disorders and disorders of gastrointestinal function and motility.
Meet the Team
Learn more about the MAST team of scientists, physicians, faculty members and other healthcare professionals who investigate the micobiome in the laboratory as well as work directly with patients.
In 2021, Cedars-Sinai researchers sampled small intestine bacteria from 251 upper endoscopy patients. Findings showed shifts in gut bacteria could impact the aging process—protecting these microbes could promote longevity.
Healio Gastroenterology spoke with Mark Pimentel, MD, executive director of Cedars-Sinai’s Medically Associated Science and Technology (MAST) Program, about the small intestine bacterial overgrowth breath test and IBS patient care.